Related references
Note: Only part of the references are listed.Improving drug response prediction by integrating multiple data sources: matrix factorization, kernel and network-based approaches
Betul Guvenc Paltun et al.
BRIEFINGS IN BIOINFORMATICS (2021)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model
Dong Wei et al.
BMC BIOINFORMATICS (2019)
Predicting drug response of tumors from integrated genomic profiles by deep neural networks
Yu-Chiao Chiu et al.
BMC MEDICAL GENOMICS (2019)
The double edge sword of fibrosis in cancer
Chelsea Chandler et al.
TRANSLATIONAL RESEARCH (2019)
RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB
William C. Reinhold et al.
CANCER RESEARCH (2019)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization
Na-Na Guan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines
Alfredo I. Sagredo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Predicting Cancer Drug Response using a Recommender System
Chayaporn Suphavilai et al.
BIOINFORMATICS (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
Anthony W. Tolcher et al.
MOLECULAR CANCER THERAPEUTICS (2018)
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations
Lauretta Odogwu et al.
ONCOLOGIST (2018)
Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature
Yoosup Chang et al.
SCIENTIFIC REPORTS (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey et al.
NATURE REVIEWS CANCER (2018)
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines
Vinodh N. Rajapakse et al.
ISCIENCE (2018)
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies
Paul Geeleher et al.
GENOME RESEARCH (2017)
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
Alberto Ballestrero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data
Yuanyuan Li et al.
BMC GENOMICS (2017)
Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes
Iva Gudernova et al.
HUMAN MOLECULAR GENETICS (2016)
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Matthew G. Rees et al.
NATURE CHEMICAL BIOLOGY (2016)
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson et al.
BLOOD (2016)
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
Aparajitha Vaidyanathan et al.
BRITISH JOURNAL OF CANCER (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Brett Wallden et al.
BMC MEDICAL GENOMICS (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Brinton Seashore-Ludlow et al.
CANCER DISCOVERY (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
Using drug response data to identify molecular effectors, and molecular omic data to identify candidate drugs in cancer
William C. Reinhold et al.
HUMAN GENETICS (2015)
The developing story of Sprouty and cancer
Samar Masoumi-Moghaddam et al.
CANCER AND METASTASIS REVIEWS (2014)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Bleomycin electrochemotherapy in elderly metastatic breast cancer patients: clinical outcome and management considerations
Luca G. Campana et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
Paul Geeleher et al.
GENOME BIOLOGY (2014)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang et al.
NUCLEIC ACIDS RESEARCH (2013)
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer
Alvaro Aytes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Adenosine Kinase: Exploitation for Therapeutic Gain
Detlev Boison
PHARMACOLOGICAL REVIEWS (2013)
CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set
William C. Reinhold et al.
CANCER RESEARCH (2012)
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Kevin G. Chen et al.
CLINICAL CANCER RESEARCH (2012)
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Stephen K. Chia et al.
CLINICAL CANCER RESEARCH (2012)
BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcala et al.
CLINICAL CANCER RESEARCH (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
Laura M. Hodges et al.
PHARMACOGENETICS AND GENOMICS (2011)
Angiotensin-Converting Enzyme N-Terminal Inactivation Alleviates Bleomycin-Induced Lung Injury
Ping Li et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
Nathatie Gaspar et al.
CANCER RESEARCH (2009)
Angiotensin inhibition and malignancies: a review
T. Rosenthal et al.
JOURNAL OF HUMAN HYPERTENSION (2009)
MOLECULAR ORIGINS OF CANCER Gene-Expression Signatures in Breast Cancer
Christos Sotiriou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Enhanced expression of hepatocyte growth factor activator inhibitor type 2-related small peptide at the invasive front of colon cancers
S. Uchiyama et al.
GUT (2007)
A safety and efficacy study of bleomycin sulfate and electroporation in patients with metastatic or locally recurrent breast cancer
V. Paramanov et al.
BREAST CANCER RESEARCH (2007)
Neoplastic transformation and tumorigenesis associated with overexpression of imup-1 and imup-2 genes in cultured NIH/3T3 mouse fibroblasts
Zae Young Ryoo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing Ras activation
I Gross et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Gene selection for sample classification based on gene expression data: study of sensitivity to choice of parameters of the GA/KNN method
LP Li et al.
BIOINFORMATICS (2001)
Bleomycin upregulates gene expression of angiotensin-converting enzyme via mitogen-activated protein kinase and early growth response 1 transcription factor
RM Day et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
Monte Carlo cross validation
QS Xu et al.
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS (2001)
Identification of cDNAs encoding two novel nuclear proteins, IMUP-1 and IMUP-2, upregulated in SV40-immortalized human fibroblasts
JK Kim et al.
GENE (2000)
Share Paper
